CompletedPhase 1NCT02609932

Effect of IFN-γ on Innate Immune Cells

Studying Chronic granulomatous disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Colorado, Denver
Principal Investigator
Daniel R. Ambruso, MD
University of Colorado, Denver
Intervention
Administration of drug (Interferon-gamma 1-b) subcutaneously(drug)
Enrollment
20 enrolled
Eligibility
18-60 years · All sexes
Timeline
20162019

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02609932 on ClinicalTrials.gov

Other trials for Chronic granulomatous disease

Additional recruiting or active studies for the same condition.

See all trials for Chronic granulomatous disease

← Back to all trials